NCT03031730 2026-02-10Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple MyelomaNational Cancer Institute (NCI)Phase 1 Terminated35 enrolled 10 charts
NCT02136134 2025-08-29Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaJanssen Research & Development, LLCPhase 3 Completed498 enrolled 15 charts